Abstract. Atrial and brain natriuretic peptides (ANP and BNP, respectively) are cardiac hormones. During cardiac development, their expression is a maker of cardiomyocyte differentiation and is under tight spatiotemporal regulation. After birth, however, their ventricular expression is only up-regulated in response to various cardiovascular diseases. As a result, analysis of ANP and BNP gene expression has led to discoveries of transcriptional regulators and signaling pathways involved in both cardiac differentiation and cardiac disease. Studies using genetically engineered mice have shed light on the molecular mechanisms regulating ANP and BNP gene expression, as well as the physiological and pathophysiological relevance of the cardiac natriuretic peptide system. In this review we will summarize what is currently known about their regulation and the significance of ANP and BNP as hormones derived from the heart.
appears that the molecular pathways involved in the reactivation of ANP and BNP gene expression are closely linked to adaptive or maladaptive cardiac signaling pathways induced in response to pathological stress. Because of the importance of these two hormones to the physiology and pathophysiology of the heart, many aspects of the molecular mechanism controlling ANP and BNP gene expression during cardiac development and in disease have been studied.
Upon their release, ANP and BNP act at multiple sites to exert diuretic, natriuretic and vasorelaxant effects [4] . Moreover, recent evidence indicates that ANP and BNP also act as paracrine factors, exerting antihypertrophic and antifibrotic effects in the heart. They exert both their hormonal and paracrine effects through activation of their common receptor, guanylyl cyclase-A (GC-A; also known as natriuretic peptide receptor-A), which is expressed in a variety of tissues, including kidney, blood vessel, adrenal gland and heart, and is coupled to an increase in the intracellular concentration of cGMP [4] . The significance of ANP/BNP-GC-A signaling in various physiological and pathophysiological settings has been examined in a number of studies using mice lacking genes encoding components of this signaling pathway. Here we review what is currently known about the transcrip-ment and a phenylephrine-responsive element (PERE), to which the transcriptional factors SRF, NKX2.5, Tbx5, GATA4/6, MEF2C and Zfp260 have been shown to bind (Fig. 1) [10, 13] . In addition, these elements have been shown to contribute singly or cooperatively to the basal and inducible activation of ANP promoter activity in cardiac cells [13] [14] [15] [16] [17] [18] [19] . NRSE, hypoxia-response element (HRE) and glucocorticoid responsive element (GRE), which are located outside the proximal promoter, also reportedly mediate inducible ANP gene transcription [20] [21] [22] [23] .
II. Transcriptional regulation of BNP gene expression
The 5'-FR of the BNP gene has also been studied so as to better understand the regulatory mechanisms governing the gene's cardiac-specific and inducible expression. A study using transgenic mice carrying a 5'-FR segment of the human BNP gene extending from -1818 to +100, or from -408 to +100, coupled to a luciferase gene (-1818hBNPluc and -400hBNPluc, respectively) showed that the proximal region of the human BNP promoter is sufficient to mediate ventricle-specific expression [24] . The luciferase activity of -1818hBNPluc was also higher in ventricular myocytes than in atrial myocytes [25] . BNP mRNA has a shorter half-life than ANP mRNA and has an AT-rich region in its 3'-UTR. This makes the gene unstable and implies post-transcriptional control of BNP gene expression [26] [27] [28] [29] . In addition, deletion analysis showed that the region extending from -127 to -40 of the human BNP 5'-FR confers cardiac-specific expression [25] . This proximal region of the human BNP promoter contains potential GATA, M-CAT and AP-1/ CRE-like elements, which are conserved among humans, rats and mice (Fig. 2) 
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I. Transcriptional regulation of ANP gene expression
Studies using transgenic mice carrying a 500-bp segment of the 5' flanking region (5'-FR) of the human ANP gene fused to a gene encoding SV40 large T antigen, a 2.4-kbp 5'-FR segment of human ANP gene fused to the chloramphenicol acetyltransferase gene or either a 638-bp or 3-kbp 5'-FR segment of the rat ANP gene fused to the luciferase gene have shown that these regions are sufficient to confer cardiac-restricted gene expression, with much higher expression in the atria than in the ventricles [5] [6] [7] . The ventricular activities of the 3-kbp, 2.4-kbp and 638-bp 5'-FR segments were down-regulated after birth, while the atrial activity remained high. These observations demonstrate that the proximal 5'-FR of the ANP gene is sufficient to recapitulate the spatial and temporal expression of the endogenous ANP gene and that the region contains sequences important for the regulation of ANP gene expression. Indeed, expression of a reporter gene driven by the proximal 5'-FR of the ANP gene in atrial or ventricular cardiac myocytes at different developmental stages showed that the region confers proper spatial and temporal activity to the ANP promoter [8, 9] . That said, there are some differences in the expression pattern between the proximal 5'-FR of the ANP gene and the intact endogenous ANP gene, which suggests the presence of regulatory elements outside the proximal 5'-FR [10] . It should be noted that in humans and mice, respectively, the ANP gene is located 8 kbp and 12 kbp downstream of the BNP gene on the same chromosome (human, chromosome 1; mouse, chromosome 4) [11, 12] . The proximal 5'-FR of the ANP gene contains two CArG boxes, two NKEs, three TBEs, two GATA sites, an A/T-rich ele- ticipate in the inducible activation of the human BNP promoter (Fig. 2) 
CArG box/Serum response element (SrE)
Two CArG boxes, also known as SREs, are present in the 5'-FR of the ANP gene, and were shown to mediate hypertrophic signaling [34] . The transcription factor serum response factor (SRF), which is known to play important roles in cardiovascular development and disease, binds to these sequences [52] . At least 
t-box binding elements (tBE)
Three T-box binding elements (TBE) have been identified in the ANP promoter [60, 61] , and the T-box transcription factors Tbx5, Tbx2, Tbx3 and Tbx20 are all thought to be involved in regulating ANP gene transcription [10] . Tbx5, whose mutation causes Holt-Oram syndrome, binds to TBE and interacts with NKX2.5 to synergistically activate ANP gene transcription [60, 61] . Tbx5 haploinsufficient mice showed marked reductions in ANP expression, while Tbx5-null mice expressed no ANP.
Myocyte enhancer factor (MEF) 2
MEF2A-D are MADS box transcription factors that bind to A/T-rich sequences in various muscle-specific genes. Mice lacking MEF2C do not express ANP and show impaired cardiac morphogenesis [62] . MEF2C reportedly binds to the low affinity A/T-rich sequence in the ANP promoter and then stimulates ANP gene transcription [18] .
NK-homeobox binding element (NKE)
A homeodomain containing the transcription factor NKx2.5 plays a critical role in cardiac development and cardiac disease [32] . Two such NKEs have been identified in the ANP promoter. 
Shear stress-responsive element (SSrE)
Multiple SSREs are located in the human BNP promoter at -652, -533 and -162. Mechanical strain reportedly activates the BNP promoter activity via SSRE [71] .
thyroid hormone-responsive element (trE)
Thyroid hormone (T3) and thyroid hormone receptor activate BNP gene transcription through TRE located at -1000 in the human BNP promoter. T3 and ET-1 act synergistically to stimulate human BNP promoter activity, and mutation of TRE reduces the response to both T3 and ET-1 [47].
IV. Regulation of ANP and BNP in cardiac myocytes
The expression and secretion of ANP and BNP is up-regulated in diseased hearts such as those showing cardiac hypertrophy or cardiomyopathy, and mechanical stress stimulates the synthesis and secretion of ANP and BNP in both atrial and ventricular cells [72] [73] [74] . In addition, neurohumoral factors, including ET-1 [75] [76] [77] [78] , thyroid hormone [79] [80] [81] , α-adrenergic agonists [29, 82, 83] , prostaglandins [84] , glucocorticoids [81, 85] and angiotensin II [86] , as well as various growth factors [87] and cytokines, including IL-1β [88, 89] , LIF, CT-1 [90] [91] [92] and TNF-α [93] , all stimulate ANP and BNP synthesis in cultured cardiac myocytes (see review in [72] ). And multiple signaling pathways comprised of such MAPK family enzymes as ERK1/2, JNK, P38MAPK and ERK5, as well as CaMKII, PKCs, Jak-STATs, Rho-ROCK and calcineurin-NFATs, are reportedly involved in the up-regulation of ANP and/or BNP [43, 46, 78, [94] [95] [96] [97] [98] [99] [100] . Thus a broad spectrum of mediators and signaling pathways are thought to contribute to the increased synthesis and secretion of ANP and BNP observed under pathological conditions.
M-CAt
The proximal human BNP promoter contains two M-CAT elements, of which the more proximal is conserved in mouse and rat. This proximal M-CAT site appears to be involved in regulating basal BNP promoter activity in both humans and rats, mediating β-adrenergic-induced human BNP promoter activity and phenylephrine-induced activation of rat BNP promoter activity [40, 42] . Although it is not yet certain which transcription factor binds to the proximal M-CAT site in the BNP promoter, it is likely that one or more TEF family transcription factors are involved, as is the case with the β-MHC and skeletal α-actin promoters [37] . Consistent with that idea, disruption of TEF-1 using a retroviral gene trap leads to the development of cardiac defects [63] .
AP-1/CrE-like
The human BNP promoter contains multiple AP-1/CRE-like binding sites, of which the proximal -111AP-1/CRE-like binding site has been shown to play an important role in the basal regulation of both human and rat BNP promoter activity [38, 43] . AP-1 site is also identified in the ANP promoter, and a c-fos/c-jun complex was shown to bind to the element [64].
NF-At
Molkentin et al. showed that the NF-AT family transcription factors act with GATA-4 to mediate phenylephrine-induced activation of the human BNP promoter. A functional NF-AT binding site is located at -972 in the human BNP promoter [46] . Mice in which both NF-ATC3 and -C4 were deleted die in utero due to abnormal cardiac development [65] . Recent studies have also shown that the TRPC1/3/6-calcineurin pathway is an upstream regulator of NF-AT-dependent transcription [66] [67] [68] [69] .
Neuron-restrictive silencer element (NrSE)
We have shown that the transcriptional repressor element NRSE, located at -552 in the human BNP promoter, represses basal BNP promoter activity and mediates the hypertrophic signaling evoked with extracellular matrix [70] . This NRSE is conserved in the rat and mouse BNP promoters. A transcriptional repressor, NRSF, binds to the element, thereby repressing promoter activity. Interestingly, NRSE is also located in the 3'UTR of the ANP promoter and is in-sels are abolished. These SMC GC-A knockout mice have normal arterial blood pressure; however, acute volume expansion, which normally causes release of ANP from the heart but does not affect blood pressure in control mice, evokes significant and rapid increases in blood pressure in SMC GC-A knockout mice. Thus SMC GC-A is apparently dispensable for chronic regulation of arterial blood pressure, but is critical for the acute regulation of the response to volume overload [114] . In addition, endothelial cell-specific deletion of GC-A accomplished using Tie2-CRE induces high blood pressure and cardiac hypertrophy, but the direct vasodilatory effect of ANP is preserved, suggesting endothelial GC-A also regulates vascular permeability and is critical for the regulation of the hypovolemic and hypotensive actions of ANP [115] .
The role of GC-A in several pathological conditions has also been studied. In a mouse model of ischemia/reperfusion injury of the heart, both genetic loss of GC-A and its pharmacological blockade alleviate ischemia/reperfusion injury, suggesting GC-A plays a role in acute inflammatory responses in the heart [116] . Supporting that notion are the findings that BNP transgenic mice subjected to myocardial infarction show greater accumulation of neutrophils in the heart and a greater susceptibility to cardiac rupture than wildtype mice [117] . On the other hand, GC-A-null mice subjected to myocardial infarction show greater susceptibility to acute heart failure and exacerbation of chronic pathological cardiac remodeling, as compared to wild-type mice. These findings are indicative of the critical role played by GC-A in the regulation of volume during the acute phase after myocardial infarction, as well as the antihypertrophic and antifibrotic effects of GC-A during the chronic phase [118] . GC-A-null mice also show increased susceptibility to heart failure due to volume overload caused by aortocaval fictula, which further highlights the importance of GC-A for volume control under conditions of pathological volume overload [119] . Chronic hypoxia and aortic constriction worsen cardiac hypertrophy in GC-A-null and cardiac-specific GC-A knockout mice, respectively, which also reflects the antihypertrophic effect of GC-A signaling [111, 120] . Finally, BNP knockout mice do not exhibit hypertension or cardiac hypertrophy, but do develop cardiac fibrosis, suggesting BNP acts via GC-A to locally regulate cardiac remodeling [121] .
B. Physiological and Pathophysiological Significance of BNP, ANP and Signaling through GC-A
The physiological functions of ANP and BNP and their receptor, GC-A, have been studied through their genetic ablation or by blocking GC-A. Genetic ablation of ANP leads to salt-sensitive hypertension in homozygous null mice [101] . In heterozygous and homozygous ANP-null mice maintained on low-salt diet, the natriuretic response to acute volume overload is diminished, as compared to wild type mice, suggesting ANP is required for the natriuretic response to volume expansion in animals on a low salt diet [102] . In rats, blockade of GC-A also results in a significant reduction in diuresis and natriuresis in response to acute volume overload [103] . Homozygous GC-A-deficient mice exhibit salt-insensitive hypertension and marked reductions in natriuresis and diuresis in response to acute volume overload [104] [105] [106] [107] . All of these findings indicate ANP acts as a circulating hormone regulating systemic blood pressure and cardiorenal homeostasis through GC-A.
GC-A-null mice also show cardiac hypertrophy with extensive interstitial fibrosis [107, 108] , and the cardiac hypertrophy observed in GC-A-null mice appears to be at least partially independent of the high blood pressure [109, 110] . Moreover, cardiac hypertrophy is observed in mice in which the CRE/loxP system was used to cardiac-specifically delete GC-A, despite preservation of all endocrine activity, including pressure-and volume-regulating effects [111] . These findings suggest ANP and BNP also act as local antihypertrophic regulators. Consistent with that idea, genetic ablation of angiotensin type IA receptor or blockade of angiotensin type I receptor significantly reduces cardiac hypertrophy and fibrosis in GC-A-null mice, suggesting the cardiac natriuretic peptide-GC-A system antagonizes the prohypertrophic signaling mediated by the angiotensin type I receptor [112] . Interestingly, there is a gender difference in the cardiac hypertrophic and fibrotic responses seen in GC-Anull mice, and androgen contributes to that gender difference in an angiotensin II type I receptor-dependent fashion [113] .
In mice with smooth muscle cell (SMC)-specific deletion of GC-A accomplished using SM22-CRE, which reduced vascular GC-A gene expression by 80%, the vasodilatory effects of ANP on isolated ves-ing. Continued efforts to identify molecular targets of natriuretic peptide system will further enhance our understanding of the role of natriuretic peptides in cardiovascular system and also of the molecular basis for the development and progression of cardiovascular diseases.
C. Concluding remarks and Perspective
Studies of ANP and BNP gene expression have led to discoveries of transcriptional regulators and signaling pathways involved in either cardiac differentiation or cardiac diseases. Still, much of molecular mediators via which the expression of ANP and BNP in myocardium is controlled remain to be characterized. It became apparent that the regulation of ANP and BNP gene expression is more complex than initially thought. More efforts to elucidate molecular mechanisms regulating ANP and BNP expression, in particular mechanisms regulating the perinatal suppression and the reactivation in diseased hearts of the expression may be necessary. Studies using genetically engineered mice have shed light on the physiological and pathophysiological relevance of the cardiac natriuretic peptide system and its downstream signal- 
